雷珠单抗与康柏西普治疗视网膜静脉阻塞继发黄斑囊样水肿的疗效比较  

Comparison of the Efficacy of Ranibizumab and Conbercept in the Treatment of Cystoid Macular Edema Secondary to Retinal Vein Occlusion

作　　者：朱剑峰[1] 陈杨磊 夏伟[1] ZHU Jianfeng;CHEN Yanglei;XIA Wei(Department of Ophthalmology,Dongtai Hospital of Traditional Chinese Medicine,Yancheng 224200,Jiangsu,China)

机构地区：[1]东台市中医院眼科,江苏盐城224200

出　　处：《系统医学》2024年第18期100-103,共4页Systems Medicine

摘　　要：目的观察并比较雷珠单抗与康柏西普在视网膜静脉阻塞(retinal vein obstruction,RVO)继发黄斑囊样水肿(cystoid macular edema,CME)治疗中的疗效。方法非随机选取2022年1月—2023年12月东台市中医院收治的120例RVO继发CME患者为研究对象,依据治疗方法不同分成两组,研究组接受雷珠单抗治疗(n=61),对照组接受康柏西普治疗(n=59)。对比两组的视力水平及黄斑中心凹视网膜厚度的改善程度、并发症发生率。结果研究组疗后6个月最佳矫正视力水平为0.48±0.08,黄斑中心凹视网膜厚度为(295.24±10.85)μm,优于对照组的0.39±0.07、(315.12±11.69)μm,差异有统计学意义(t=2.449、2.323,P均<0.05)。两组临床疗效及并发症发生率比较,差异无统计学意义(P均>0.05)。结论雷珠单抗、康柏西普用于RVO继发CME的疗效差异性甚微,比较而言前者的效果较好,治疗中可根据患者的实际情况酌情选择。Objective To observe and compare the efficacy of ranibizumab and conbercept in the treatment of cystoid macular edema(CME)secondary to retinal vein obstruction(RVO).Methods A total of 120 patients with RVO secondary CME admitted to Dongtai Hospital of Traditional Chinese Medicine from January 2022 to December 2023 were non-randomly selected as the study subjects,and divided into two groups according to different treatment methods.The study group received Leizumab treatment(n=61),and the control group received Compaximab treatment(n=59).The visual acuity level,the improvement degree of macular foveal retinal thickness and the incidence of complications were compared between the two groups.Results The best corrected visual acuity level of the study group was 0.48±0.08 and the thickness of macular fovea retina was(295.24±10.85)μm,which was better than that of the control group 0.39±0.07 and(315.12±11.69)μm,and the differences were statistically significant(t=2.449,2.323,both P<0.05).There were no significant differences in clinical efficacy and complication rate between the two groups(both P>0.05).Conclusion There is little difference in the efficacy of lezumab and Compaximab in the treatment of RVO secondary CME,but the former has a better effect,and the treatment can be selected according to the actual situation of patients.

关 键 词：视网膜静脉阻塞 继发性黄斑水肿 视力 治疗效果 

分 类 号：R453[医药卫生—治疗学]